Gene Therapy Manufacturers Are Highly Sought Acquisition Targets
Scale And Outsourcing Demands Lead To A Spree In Acquisitions
Given the transformative nature of regenerative medicines, treatments yielding greatly improved patient responses that now exist as viable products on the market, cell and gene drug developers over the past several years have been drawing deal attention. Not only through collaborative partnerships, but also as acquisition targets.
